CN1903254A - Compound medicine for treating wind-heat type cold and preparing method thereof - Google Patents
Compound medicine for treating wind-heat type cold and preparing method thereof Download PDFInfo
- Publication number
- CN1903254A CN1903254A CN 200610111509 CN200610111509A CN1903254A CN 1903254 A CN1903254 A CN 1903254A CN 200610111509 CN200610111509 CN 200610111509 CN 200610111509 A CN200610111509 A CN 200610111509A CN 1903254 A CN1903254 A CN 1903254A
- Authority
- CN
- China
- Prior art keywords
- parts
- volatile oil
- medicine
- radix
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 137
- 150000001875 compounds Chemical class 0.000 title claims description 14
- 238000000034 method Methods 0.000 title abstract description 9
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 101
- 239000000341 volatile oil Substances 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000010231 banlangen Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 7
- -1 soaked reflux Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 241000555712 Forsythia Species 0.000 claims description 4
- 241000245240 Lonicera Species 0.000 claims description 4
- 241001072983 Mentha Species 0.000 claims description 4
- 235000014435 Mentha Nutrition 0.000 claims description 4
- 241000951473 Schizonepeta Species 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000208843 Arctium Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 34
- 229940079593 drug Drugs 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 239000002510 pyrogen Substances 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 17
- 230000036760 body temperature Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000194017 Streptococcus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 12
- 230000001681 protective effect Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 241000193998 Streptococcus pneumoniae Species 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 10
- 238000012449 Kunming mouse Methods 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 230000002949 hemolytic effect Effects 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 201000000297 Erysipelas Diseases 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000117280 Naematelia aurantialba Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-M 2-nitrophenolate Chemical compound [O-]C1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-M 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese-medicine for treating cold is prepared from 9 Chinese-medicinal materials including arctium fruit, honeysuckle flower, mint, liquorice root, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of compound medicine for the treatment of anemopyretic cold and preparation method thereof.
Background technology
Alleged flu of modern Chinese medicine and doctor trained in Western medicine upper respiratory tract infection (flu), the two clinical indication is identical.The primary disease clinical manifestation is a feature with headache, heating, aversion to cold, nasal obstruction, watery nasal discharge, cough, pharyngalgia and general malaise, have a medical check-up visible nasal mucosa hyperemia, edema and more secretions, pharyngeal mild hyperaemia.Though but most of patients 1 week spontaneous recovery, the system of Himdu logic is developed the work of sound and quality of life, often needs medication treatment.
Upper respiratory tract infection 70-80% is above for viral infection causes, mainly contains rhinovirus, influenza virus, parainfluenza virus, Coxsackie virus, respiratory syncytial virus, looks at virus etc.Bacterial infection can directly or after viral infection take place, and for seeing, is hemophilus influenza, streptococcus pneumoniae and staphylococcus etc. with the hemolytic chain coccobacillus secondly more.Accidental gram negative bacilli.Its infection mainly show as rhinitis, pharyngolaryngitis or tonsillitis.
Modern medicine thinks how flu is caused by virus, because Western medicine does not have specially good effect Hangzhoupro virus drugs at present, and clinical antiviral drugs amantadine, rimantadine commonly used can cause central vertigo and the appearance of drug resistance strain rapidly, virazole can cause that to some case hemopoietic systems such as anemia, leukopenia change, zoopery proves to have and causes rugged possibility, so western medical treatment mainly is an anti symptom treatment.Most of clinically Coritabs are compound recipe, often are made up of antipyretic analgesic, antiallergic agent and anti-nasal congestion medicine (shrinking the nasal mucosa vessels medicine) etc.Wherein containing Stay Trim will be stopped to sell by national explicit order the end of the year 2000 because of its causing bleeding property apoplexy danger.Mainly contain in the market second phthalein atmosphere base phenol and pseudoephedrine hydrochloride compound preparation.The Hangzhoupro bacterium medicine person of use is also arranged, and effect is not really desirable, and forms Hangzhoupro bacterium drug dependence thus more, and its consequence is paid attention to by people day by day.
A large amount of clinical practices show in China, and Chinese medicine is possessed real skills on anti-curing cold, and has characteristics such as remission is very fast, side effect is less.
Alleged flu of Chinese medicine and doctor trained in Western medicine upper respiratory tract infection (flu) indication basically identical, traditional traditional Chinese medical science then is called cold, emits wind.The traditional Chinese medical science thinks that flu is a kind of exogenous diseases that is caused by the ailment said due to cold or exposure invasion and attack.Clinical is primary symptom with headache, nasal obstruction, watery nasal discharge, sneeze, aversion to cold, heating, floating pulse etc.
Pigtail card typing aspect generally is divided into flu types such as wind and cold, wind heat, heat-damp in summer and weakness type cold, the summer-wet type morbidity with obvious relation is arranged season, weakness type cold then with patient's body constitution and double demonstrate,prove in spite of illness relevant, so fundamental type actual be wind and cold, wind heat amphitypy.These two kinds flu etiology and pathogenesis, symptom, Therapeutic Principle and medication difference are very big.Many families all have the Chinese patent medicine of treatment flu, eaten many medicines after the somebody catches a cold, but disease do not alleviate.Key is there is not diagnosis and prescription.
Summary of the invention
It is undesirable that the technical issues that need to address of the present invention just are to overcome the western medicine result that has the treatment anemopyretic cold now, and the defective of certain side effect arranged, a kind of compound medicine for the treatment of anemopyretic cold and preparation method thereof is provided, and its treatment anemopyretic cold is evident in efficacy, purity is high, side effect is little.
For addressing the above problem, the present invention adopts following technical scheme:
A kind of compound medicine for the treatment of anemopyretic cold of the present invention, the preparation parts by weight of raw materials proportioning of the active component that it is contained is: 280～380 parts of Fructus Arctiis, 780～880 parts of Flos Loniceraes, 450～550 parts of Fructus Forsythiaes, 280～380 parts of Herba Menthaes, 280～380 parts of Herba Schizonepetaes, 450～550 parts of Radix Isatidiss, 280～380 parts of Rhizoma Et Radix Notopterygiis, 450～550 parts of Folium Isatidiss, Radix Glycyrrhizae 110-210 part.
Preferably, the preparation parts by weight of raw materials proportioning of the active component that the present invention is contained is: 333 parts of Fructus Arctiis, 833 parts of Flos Loniceraes, 500 parts of Fructus Forsythiaes, 333 parts of Herba Menthaes, 333 parts of Herba Schizonepetaes, 500 parts of Radix Isatidiss, 333 parts of Rhizoma Et Radix Notopterygiis, 500 parts of Folium Isatidiss, 167 parts in Radix Glycyrrhizae.
The preferred dosage form of compound medicine of the present invention is a granule.
The present invention discloses a kind of preparation method for the treatment of the compound medicine of anemopyretic cold, it may further comprise the steps: a: the extraction of Fructus Forsythiae, Flos Lonicerae, Herba Menthae, Herba Schizonepetae, Rhizoma Et Radix Notopterygii volatile oil; B: the inclusion of volatile oil; C: the extraction of Fructus Arctii, Radix Isatidis, Folium Isatidis, Radix Glycyrrhizae; D: the preparation of granule.
The extraction step of volatile oil described in the inventive method is: Fructus Forsythiae, Flos Lonicerae, Herba Menthae, Herba Schizonepetae, Rhizoma Et Radix Notopterygii are added 4 times of water, soaked 1 hour, reflux, extract, volatile oil 4 hours gets volatile oil, and other collects by device respectively for aqueous solution after the distillation and medicinal residues.
The inclusion of volatile oil described in the inventive method is: step a gained volatile oil is ground with 8 times of amount beta-schardinger dextrin-s, 16 times of water, and the grinding gap is 5um, and milling time is 20 minutes inclusions, 40 ℃ of drying under reduced pressure, pulverize, cross 40 mesh sieves, get the volatile oil inclusion complex.
Fructus Arctii described in the inventive method, Radix Isatidis, Folium Isatidis, the extraction step of Radix Glycyrrhizae is: will extract medicinal residues and Fructus Arctii behind the volatile oil, Radix Isatidis, Folium Isatidis, Radix Glycyrrhizae mixes and adds 10 times in water respectively, 8 times, decoct 2 times, time was respectively 2 hours, 1 hour, collecting decoction, filter, aqueous solution when filtrate and extraction volatile oil after the distillation merges, being concentrated into relative density is the clear paste of 1.10～1.12 (60～75 ℃), put and be chilled to room temperature, slowly add ethanol while stirring, make to contain alcohol amount and reach 70%, left standstill 12 hours, the leaching supernatant reclaims ethanol and is concentrated into the clear paste that relative density is 1.20～1.22 (60～75 ℃).
The preparation process of granule described in the inventive method is: clear paste is mixed with volatile oil inclusion complex and dextrin, steviosin, make granule altogether.
Granule of the present invention is carried out packed, every packed dose is 6g, and every bag contains Arctiin and is no less than 50mg.
The method of administration of medicine of the present invention is: oral, and every day three times, each one bag.
Among the present invention, the Fructus Arctii dispelling wind and heat pathogens, the lung qi dispersing rash, resolving toxin and disinhibiting the throat can be used for anemopyretic cold, cough with copious phlegm, measles, rubella, laryngopharynx swelling and pain, mumps erysipelas, carbuncle sore tumefacting virus.Flos Lonicerae function heat-clearing and toxic substances removing, wind-heat dissipating can be used for carbuncle furuncle, sore throat, erysipelas, warm blood fulminant dysentery, anemopyretic cold, epidemic febrile disease heating.The Fructus Forsythiae heat-clearing and toxic substances removing, dispersing swelling and dissipating binds.Can be used for carbuncle, scrofula, acute mastitis, erysipelas, anemopyretic cold, epidemic febrile disease is from the beginning of, warm joining the army, the hyperpyrexia excessive thirst, coma is sent out speckle, the pyretic stranguria urine retention.The Herba Menthae dispelling wind-heat.The refresh oneself, rash.Can be used for anemopyretic cold, pathogenic wind-warm from the beginning of, headache, conjunctival congestion, sore throat, aphtha, rubella, measles, breast side of body feeling of distension and oppression.The hot gas perfume (or spice) that looses of Herba Schizonepetae is longer than and delivers diffusing wind, and tepor is not strong, this medicine is mild, the exterior cold exterior heat all available it.The function of Radix Isatidis tool heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving is used for purple dark, the mumps of maculae caused by violent heat pathogen, crimson tongue, sore throat, scarlet fever, major part pestilence, erysipelas, carbuncle.The Rhizoma Et Radix Notopterygii cold expelling dispels the wind, dehumidifying, pain relieving.Be used for the anemofrigid cold headache, rheumatic arthralgia, aching pain in should and back.Folium Isatidis is famous simply heat and toxic materials clearing away medicine, has good anti-infectious function, and is commonly used with treatment various bacterial and viral infection.Experiment points out that the Folium Isatidis decoct all has killing action to multiple dysentery bacterium, and meningococcus is also had killing action; The leaf of Isatis indigotica Fort. and Acanthaceous indigo has certain inhibitory action to staphylococcus aureus and Hemolytic streptococcus.Zoopery confirms further that then Folium Isatidis has antipyretic effect to the heating of animal, can strengthen the cytophagous phagocytic activity of body, reduces the permeability of blood capillary, thereby has antiinflammation, even aseptic inflammation is also had effect.Folium Isatidis bitter in the mouth cold in nature, energy heat clearing away, detoxifcation, cooling blood for hemostasis, commonly used with diseases such as treatment epidemic febrile disease intenseness of heat excessive thirst, erysipelas, haematemesis, epistaxis, sore throat, aphtha, swollen ulcer drugs.Radix Glycyrrhizae is the Chinese medicine of using always, and property is flat, sweet in the mouth, the function of tool spleen reinforcing, lung moistening, detoxifcation, coordinating the actions of various ingredients in a prescription.Can lower or alleviate bias, the toxicity of other drug, tool is auxiliary, coordination, flavored action.
Due to evil criminal's table, the lung qi that the present invention is directed to anemopyretic cold and be wind heat become estranged.Symptom shows as heating weight, micro evil wind, distending pain in the head, antiperspirant, red swelling and pain of throat, cough, expectorant sticking or yellow, have a stuffy nose yellow thick nasal discharge, thirst and liking drink, red, the little Huang of white and thin fur in the tip of the tongue limit is arranged.Based on relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, select to have the medicine of antipyretic and antidote functions preferably, with hot cold it is reached thoroughly, by separating outward.
Of the present inventionization sanction ancient prescription is combined into a kind of new Chinese medicine for the treatment of anemopyretic cold, and compatibility is precise and appropriate, and effect is definite, and clinical efficacy is remarkable.
The present invention writes out a prescription less, and production technology advanced person is beneficial to suitability for industrialized production.
The specific embodiment
Embodiment 1
A: the extraction of volatile oil: Flos Lonicerae 780g, Fructus Forsythiae 550g, Herba Menthae 280g, Herba Schizonepetae 380g, Rhizoma Et Radix Notopterygii 280g, add about 8280mL water, soaked 1 hour, reflux, extract, volatile oil 4 hours gets the about 8.5mL of volatile oil, and aqueous solution after the distillation and medicinal residues device are in addition collected;
B: the inclusion of volatile oil: gained volatile oil 8.5mL, with about 68g beta-schardinger dextrin-, 136mL water grinds, and the grinding gap is 5um, and milling time is 20 minutes inclusions, and 40 ℃ of drying under reduced pressure of inclusion complex are pulverized, and cross 40 mesh sieves, get the about 75g of inclusion complex of volatile oil;
C: the extraction of Fructus Arctii etc.: with medicinal residues and the Fructus Arctii 380g behind the extraction volatile oil among the step a, Radix Isatidis 450g, Folium Isatidis 550g, Radix Glycyrrhizae 110g, add water 33600mL respectively, 26880mL, decoct 2 times, time was respectively 2 hours, 1 hour, collecting decoction, filter, the aqueous solution that extracts among filtrate and the step a after volatile oil distills merges, being concentrated into relative density is the clear paste of 1.10～1.12 (60～75 ℃), puts and is chilled to room temperature, slowly adds ethanol while stirring, make and contain alcohol amount and reach 70%, left standstill 12 hours, the leaching supernatant reclaims ethanol and is concentrated into the clear paste 616g that relative density is 1.20～1.22 (60～75 ℃);
E: the preparation of granule: the volatile oil inclusion complex 75g and dextrin 518g, the steviosin 5g that prepare among the 616g clear paste for preparing among the step c and the step b are mixed, make granule 1000g altogether.
Embodiment 2
A: the extraction of volatile oil: Flos Lonicerae 880g, Fructus Forsythiae 450g, Herba Menthae 380g, Herba Schizonepetae 280g, Rhizoma Et Radix Notopterygii 380g, add 10280mL water, soaked 1 hour, reflux, extract, volatile oil 4 hours gets volatile oil 10.5mL, and aqueous solution after the distillation and medicinal residues device are in addition collected;
B: the inclusion of volatile oil: gained volatile oil 10.5mL, with about 84g beta-schardinger dextrin-inclusion, 169mL water grinds, and the grinding gap is 5um, and milling time is 20 minutes inclusions, and 40 ℃ of drying under reduced pressure of inclusion complex are pulverized, and cross 40 mesh sieves, get the about 92g of inclusion complex of volatile oil;
C: the extraction of Fructus Arctii etc.: with medicinal residues and the Fructus Arctii 280g behind the extraction volatile oil among the step a, Radix Isatidis 550g, Folium Isatidis 450g, Radix Glycyrrhizae 210g mixes, add water 42600mL respectively, 34080mL water, decoct 2 times, time was respectively 2 hours, 1 hour, collecting decoction, filter, the aqueous solution that extracts among filtrate and the step a after volatile oil distills merges, being concentrated into relative density is the clear paste of 1.10～1.12 (60～75 ℃), puts and is chilled to room temperature, slowly adds ethanol while stirring, make and contain alcohol amount and reach 70%, left standstill 12 hours, the leaching supernatant reclaims ethanol and is concentrated into the about 781g of clear paste that relative density is 1.20～1.22 (60～75 ℃);
E: the preparation of granule: volatile oil inclusion complex 92g, the about 394g of dextrin, steviosin 5g among clear paste 781g among the step c and the step b are mixed, make granule 1000g altogether.
Embodiment 3
A: the extraction of volatile oil: Flos Lonicerae 833g, Fructus Forsythiae 500g, Herba Menthae 333g, Herba Schizonepetae 333g, Rhizoma Et Radix Notopterygii 333g, add 9328mL water, soaked 1 hour, reflux, extract, volatile oil 4 hours gets volatile oil 9.6mL, and aqueous solution after the distillation and medicinal residues device are in addition collected;
B: the inclusion of volatile oil: gained volatile oil 9.6mL, with 76.8g beta-schardinger dextrin-inclusion, 40 ℃ of drying under reduced pressure of inclusion complex are pulverized, and cross 40 sieves, get the about 84g of inclusion complex of volatile oil;
C: the extraction of Fructus Arctii etc.: with medicinal residues and the Fructus Arctii 333g behind the extraction volatile oil among the step a, Radix Isatidis 500g, Folium Isatidis 500g, Radix Glycyrrhizae 167g, add water 38320mL water respectively, 30656mL water, decoct 2 times, time was respectively 2 hours, 1 hour, collecting decoction, filter, the aqueous solution that extracts among filtrate and the step a after volatile oil distills merges, and being concentrated into relative density is the clear paste of 1.10～1.12 (60～75 ℃), put and be chilled to room temperature, slowly add ethanol while stirring, make to contain alcohol amount and reach 70%, left standstill 12 hours, the leaching supernatant reclaims ethanol and is concentrated into the about 702g of clear paste that relative density is 1.20～1.22 (60～75 ℃);
E: the preparation of granule: the clear paste 702g among the step c is mixed with volatile oil inclusion complex 76.8g, dextrin 470g, steviosin 5g among the step b, make granule 1000g altogether.
The described granule of embodiment 1-3 carries out packed, and every packed dose is 6g, and every bag contains Arctiin and is no less than 50mg.
The method of administration of the granule of embodiment 1-3 preparation is: oral, and every day three times, each one bag.
The results of pharmacodynamic test of embodiment 4 medicines of the present invention
1 test material
1.1 experimental animal
The KM mice, the male and female dual-purpose; The Wistar rat, the male and female dual-purpose
1.2 test drug
Be subjected to reagent: the granule of the embodiment of the invention 3 preparations.
Positive control drug: FENGRE GANMAO KELI, Shandong Kongfu Pharmaceutical Co., Ltd., lot number: 4154352.
2 contents of the test
2.1 medicine analgesic activity research of the present invention
2.1.1 medicine of the present invention causes the influence of the pain mice threshold of pain to hot plate
[1]
The heat-obtaining plate screens (55 ℃ ± 0.5 ℃ of qualified female KM mice, the person that licks the metapedes in the 5s-30s) 50, body weight (20 ± 2) g, be divided into ordinary water matched group, positive drug (FENGRE GANMAO KELI) group and the large, medium and small dosage group of medicine of the present invention at random by body weight, each measures hot plate pain threshold 2 times before organizing the mouse stomach administration, averages as basic pain threshold.Each organizes mice by the gastric infusion of dosage shown in the table 1, the large, medium and small dosage of medicine wherein of the present invention is equivalent to 20 times, 10 times, 5 times of people's clinical application amount respectively, positive drug is equivalent to 10 times of people's clinical application amount, the ordinary water matched group is irritated stomach equivalent ordinary water, every day, gastric infusion was 1 time, continuous 5 days, each treated animal feed water inlet was not limit.
Respectively organize mice hot plate pain threshold 1 time respectively at 30min, 60min, 90min mensuration after the last administration, the threshold of pain surpasses the 60s mice takes out in order to avoid scald rapidly, and pain threshold is in 60s.
The results are shown in Table 7.
Table 1 medicine of the present invention to hot plate method cause pain mice pain threshold influence (x ± s, n=10)
| Group | Dosage/gkg -1 | Pain threshold/s before the medicine | 30min/s behind the medicine | 60min/s behind the medicine | 90min/s behind the medicine |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 13.792±3.716 13.628±3.728 13.122±3.609 15.158±4.702 14.594±3.983 | 18.359±6.822 15.496±9.493 13.939±4.305 15.535±7.792 16.279±8.011 | 10.725±5.301 15.861±6.949 11.490±4.515 18.901±7.795 * 15.339±9.516 | 11.926±4.292 17.145±11.635 12.969±8.613 12.931±7.417 9.877±3.593 |
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows, dosage group mice pain threshold and the comparison of ordinary water group in the 60min medicine of the present invention after the administration, and difference has significance meaning (P＜0.05).Show that dosed administration 60min can cause the pain pain threshold by significant prolongation mice hot plate in the medicine of the present invention, and analgesic activity is preferably arranged.
2.1.2 medicine Dichlorodiphenyl Acetate of the present invention causes the influence of mouse writhing reaction
[2]
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, by body weight random packet (same 2.1.1), each organizes mouse stomach administration or ordinary water (the same 2.1.1 of dosage), and every day, gastric infusion was 1 time, and continuous 5 days, each treated animal feed water inlet was not limit.
30min after the last administration, each Mus lumbar injection 0.6% acetic acid 0.1mL/10g observes at once, and what mice in time (promptly turn round body incubation period) of the 1st writhing response and the 15min appearred in the record mice turns round the body number of times.
The results are shown in Table 2.
Table 2 XIAOER ZHIKE TANGJIANG Dichlorodiphenyl Acetate cause mouse writhing reaction influence (x ± s, n=10)
| Group | Dosage/gkg -1 | Number of animals/only | Turn round body incubation period/s | Turn round body/time | Analgesia rate/% |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 10 10 10 10 10 | 172.8±57.294 237.5±89.426 261.1±88.903 * 332.7±82.550 ***△ 251.2±95.457 * | 28.3±10.404 23.1±7.637 25.1±11.140 15.0±9.201 **△ 23.1±7.795 | - 18.4 11.3 47.0 18.4 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001; Compare with the positive drug group,
△P＜0.05.
Turn round body analgesia rate=(the ordinary water group is on average turned round body number of times-administration group and on average turned round the body number of times)/ordinary water group and on average turn round body number of times * 100%
The result shows, compare with the ordinary water group, the large, medium and small dosage tool of medicine of the present invention can cause (difference P＜0.05 incubation period that mouse writhing reacts by significant prolongation acetic acid, P＜0.001, P＜0.05), in the medicine of the present invention low dose of can reduce significantly that acetic acid causes the mouse writhing reaction turn round the body number of times, show that cold granules has analgesic activity preferably.
2.2 medicine antiinflammatory action test of the present invention
2.2.1 medicine xylol of the present invention causes the influence of mice auricle swelling
[3]
Get 50 of KM mices, male, body weight (20 ± 2) g, by body weight random packet (same 2.1.1 divides into groups), each organizes mouse stomach administration (dosage 2.1.1), and the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time, continuous 5 days.
Behind last gastric infusion or the ordinary water 1h, two sided coatings 0.02mL caused by dimethylbenzene xylene inflammation before and after each mouse right ear, the execution mice is cut ears and lays round auricle at same position respectively with 9mm (diameter) card punch behind the 4h, weighs, and calculates the swelling rate.
The swelling rate=(auris dextra sheet weight-left auricle is heavy)/left auricle is heavy
The results are shown in Table 3.1
Table 3 XIAOER ZHIKE TANGJIANG xylol cause mice auricle swelling influence (x ± s, n=10)
| Group | Dosage/gkg -1 | Number of animals/only | The ear swelling rate | Suppression ratio/% |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 10 10 10 10 10 | 0.836±0.304 0.644±0.229 0.501±0.245 * 0.572±0.238 * 0.548±0.399 | - 23.0 40.1 31.6 34.4 |
Annotate: compare with the ordinary water group,
*P＜0.05.
Inhibitory rate of intumesce=(the average ear swelling rate of the ordinary water group-average ear swelling rate of administration the group)/average ear swelling rate of ordinary water group * 100%
The result shows, compares with the ordinary water group, and the big or middle dosage of gout granules all can reduce mice caused by dimethylbenzene xylene auricle edema rate (being P＜0.05), and the result shows that the big or middle dosage xylol of gout granules causes mice auricle swelling and has good inhibition effect.
2.2.2 medicine Dichlorodiphenyl Acetate of the present invention causes the influence that the mouse peritoneal capillary permeability increases
[4]
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, by body weight random packet (same 2.1.1 divides into groups), each organizes mouse stomach administration (the same 2.1.1 of dosage), and the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time, and continuous 5 days, each was organized mice feed water inlet and is not limit.
1h behind the last filling stomach, each organizes mouse tail vein injection 0.5% azovan blue 0.1mL10g
-1(with weighing machine), lumbar injection 0.6% acetum 0.1mL10g immediately
-1, take off cervical vertebra behind the 20min and put to death, cut off skin of abdomen, divide with the 6mL normal saline and wash the abdominal cavity for several times, collect cleaning mixture, add normal saline after the merging to 10mL, with the centrifugal 15min of 3000rpm, get supernatant and measure absorbance in spectrophotometer 590nm place.The results are shown in Table 4.
Table 4 medicine Dichlorodiphenyl Acetate of the present invention cause the influence that the mouse peritoneal capillary permeability increases (x ± s, n=10)
| Group | Dosage/gkg -1 | Number of animals/only | Absorbance | Suppression ratio/% |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 10 10 10 10 10 | 0.213±0.0960 0.166±0.0330 0.210±0.0592 0.209±0.0553 △ 0.126±0.0545 * | - 22.1 1.4 1.8 40.8 |
Annotate: compare with the ordinary water group,
*P＜0.05; Compare with positive drug,
△P＜0.05.
Suppression ratio=(ordinary water group mean light absorbency value-administration group mean light absorbency value)/ordinary water group mean light absorbency value * 100%
The result shows, compares with the ordinary water group, and medicine low dose of the present invention can significantly reduce the mouse peritoneal transudate absorbance (P＜0.05) due to the acetic acid; The result shows that the mouse peritoneal capillary permeability that medicine low dose of the present invention can obviously suppress due to the acetic acid increases, and reduces its inflammation and oozes out, and antiinflammatory action is preferably arranged.
2.2.3 medicine on Carrageenan of the present invention causes the influence of rat paw edema
[5]
Get 50 of Wistar rats, male, by body weight it is divided into the large, medium and small dosage group of ordinary water group, positive drug control group and medicine of the present invention, 10 every group at random.Each organizes rat by the gastric infusion of dosage shown in the table 5, and wherein positive drug is 2.1gkg
-1, being equivalent to 5 times of people's clinical application amount, medicine heavy dose of the present invention is 9.9gkg
-1, middle dosage is 4.9gkg
-1, low dose is 2.5gkg
-1Be equivalent to 10 times, 5 times, 2.5 times of people's clinical application amount respectively; The ordinary water group is irritated stomach equivalent ordinary water.Irritate stomach every day 1 time, continuous 5 days.Each is organized the rats eating water inlet and is not limit.
1h behind last gastric infusion or the ordinary water, every group of rat right hind leg foot plantar subcutaneous injection 1% carrageenin 0.1mL/ only, respectively at before the injection carrageenin, injection 30min, injection 1h, injection 2h, injection 4h, injection 6h measure rat foot girth, to calculate the swelling degree.
Girth the results are shown in Table 5 before swelling degree=(girth before injection back girth-injection)/injection.
Table 5 medicine on Carrageenan of the present invention cause the rat paw edema degree influence (x ± s, n=10)
| Group | Swelling 30min | Swelling 1h | Swelling 2h | Swelling 4h | Swelling 6h |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | 0.147±0.047 0.131±0.047 0.138±0.076 0.110±0.051 0.105±0.032 * | 0.173±0.064 0.157±0.045 0.147±0.119 0.132±0.082 0.124±0.029 * | 0.221±0.093 0.218±0.089 0.193±0.115 0.203±0.077 0.183±0.028 | 0.405±0.146 0.429±0.100 0.404±0.150 0.381±0.130 0.353±0.037 | 0.504±0.175 0.487±0.071 0.503±0.161 0.457±0.141 0.397±0.061 |
Annotate: compare with the ordinary water group,
*P＜0.05.
The result shows, medicine small dose group rat paw edema degree of the present invention and ordinary water group are relatively, 30min, 1h difference have the significance meaning behind the injection carrageenin, the result shows, medicine low dose of the present invention to rat injection carrageenin after 30min, 1h rat paw edema after significant inhibitory effect is arranged.
2.3 the refrigeration function of medicine of the present invention test:
2.3.1 medicine of the present invention is to 2,2, 4-dinitrophenol causes the influence of rat fever
[6]:
Get the Wistar rat, male, body weight (200 ± 20) g surveys body temperature (anus temperature) every day 1 time, and for three days on end, experiment day is surveyed body temperature 2 times, chooses 50 of the rats that the body temperature fluctuation is no more than 0.3 ℃, divides 5 groups, 10/group (same 2.2.3 divides into groups).The average of 2 body temperature of rat that the day record with experiment as each group rat administration before basal body temperature.Each organizes gastric infusion (the same 2.2.3 of dosage), every day 1 time, continuous 5 days.Each treated animal feed water inlet is not limit.
Behind the last administration 1h, each organizes rat back subcutaneous injection 2,2, 4-dinitrophenol solution 1mLkg
-1Pyrogenicity is measured the body temperature of respectively organizing rat respectively at 0.5h, 1.0h, 1.5h, 2.0h, 2.5h, 3h after the pyrogenicity.
The results are shown in Table 6.
Table 6 medicine of the present invention is to 2,2, 4-dinitrophenol cause rat fever influence (x ± s, n=10)
| Group | Basal body temperature/℃ | Pyrogenicity 0.5h/℃ | Pyrogenicity 1.0h/℃ | Pyrogenicity 1.5h/℃ | Pyrogenicity 2.0h/℃ | Pyrogenicity 2.5h/℃ | Pyrogenicity 3.0h/℃ |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | 37.610 ±0.520 37.786 ±0.321 37.640 ±0.298 37.723 ±0.283 37.786 ±0.320 | 38.765 ±0.285 38.610 ±0.363 38.408 ±0.297 * 38.395 ±0.247 ** 38.580 ±0.148 | 38.980 ±0.374 39.236 ±0.291 39.000 ±0.378 39.200 ±0.245 39.090 ±0.197 | 39.379 ±0.212 39.153 ±0.428 39.016 ±0.467 * 39.153 ±0.312 *** 38.838 ±0.341 | 39.330 ±0.306 39.180 ±0.316 38.904 ±0.356 ** 39.050 ±0.246 * 39.250 ±0.246 | 38.994 ±0.265 38.974 ±0.313 38.785 ±0.382 38.968 ±0.268 38.859 ±0.293 | 39.130 ±0.183 39.050 ±0.272 38.835 ±0.279 * 38.659 ±0.219 ***△△ 38.882 ±0.130 * |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01,
* *P＜0.001; Compare with the positive drug group,
△ △P＜0.01.
The result shows, compares with the ordinary water group, and the heavy dose of group of medicine of the present invention 0.5h (P＜0.05), 1.5h (P＜0.05), 2.0h (P＜0.01), 3h (P＜0.05) body temperature difference after pyrogenicity have statistical significance; Dosage group 0.5h (P＜0.01), 1.5h (P＜0.0001), 2.0h (P＜0.05), 3h (P＜0.001) body temperature and ordinary water group difference after pyrogenicity has statistical significance in the medicine of the present invention, and compare with the positive drug group, 3.0h difference has highly significant meaning (P＜0.01) after pyrogenicity; Medicine small dose group of the present invention 3h body temperature and ordinary water group difference after pyrogenicity have significance meaning (P＜0.01).
The result shows that medicine of the present invention can significantly suppress 2, and 2, 4-dinitrophenol pyrogenicity rat temperature raises, better solutions heat effect again.
2.3.2 medicine of the present invention causes the influence of rat fever to the draft beer yeast
[7]:
Get the Wistar rat, male, body weight (200 ± 20) g surveys body temperature (anus temperature) every day 1 time, and for three days on end, experiment day is surveyed body temperature 2 times, chooses 50 of the rats that the body temperature fluctuation is no more than 0.3 ℃, divides 5 groups, 10/group (same 2.2.3 divides into groups).The average of 2 body temperature of rat that the day record with experiment as each group rat administration before basal body temperature.Each organizes the young beer sterilised yeast suspension 10mLkg of rat back subcutaneous injection 10%
-1Pyrogenicity.
6h after the pyrogenicity, it is inferior that each organizes gastric infusion (the same 2.2.3 of dosage), measures the body temperature 1 time of respectively organizing rat respectively at irritating 0.5h, 1h behind the stomach, 2h, 4h, 6h, 8h.
The results are shown in Table 7.
Table 7 medicine of the present invention to the young beer yeast cause rat fever influence (x ± s, n=10)
| Group | Before the medicine/℃ | Pyrogenicity 6h/℃ | 30m behind the medicine/℃ | 1h behind the medicine/℃ | 2h behind the medicine/℃ | 4h behind the medicine/℃ | 6h behind the medicine/℃ | 8h behind the medicine/℃ |
| Dosage group small dose group in the heavy dose of group of ordinary water group positive drug group | 37.600 ±0.507 37.723 ±0.388 37.634 ±0.351 37.806 ±0.339 37.732 ±0.383 | 39.203 ±0.459 39.195 ±0.252 39.188 ±0.647 39.173 ±0.285 39.198 ±0.532 | 39.799 ±0.487 39.718 ±0.343 39.409 ±0.306 *△ 39.670 ±0.413 39.303 ±0.493 *△ | 39.907 ±0.492 39.932 ±0.240 39.385 ±0.450 *△△ 39.622 ±0.345 △ 39.426 ±0.495 *△ | 39.959 ±0.505 39.752 ±0.184 39.484 ±0.446 * 39.530 ±0.382 * 39.535 ±0.374 * | 39.598 ±0.405 39.616 ±0.320 38.940 ±0.336 ***△△△ 39.331 ±0.347 39.128 ±0.447 *△ | 39.490 ±0.511 39.375 ±0.270 38.841 ±0.531 *△ 39.130 ±0.380 39.112 ±0.468 | 39.220 ±0.492 38.945 ±0.344 38.611 ±0.467 * 38.970 ±0.291 38.732 ±0.490 * |
Annotate: compare with the ordinary water group,
*P＜0.05,
*Compare with the positive drug group P＜0.01,
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.01.
The result shows, 30min, 1h after the administration, and medicine of the present invention large and small dosage group rat temperature and ordinary water group be more variant significance meaning (P＜0.05); 2h after the administration, medicine of the present invention large, medium and small dosage group rat temperature and ordinary water group be more variant significance meaning (P＜0.05); 4h after the administration, medicine of the present invention heavy dose of group rat temperature and ordinary water group be more variant a highly significant meaning (P＜0.001), and medicine small dose group rat temperature of the present invention and ordinary water group be more variant significance meaning (P＜0.05); 6h after the administration, medicine of the present invention heavy dose of group rat temperature and ordinary water group be more variant significance meaning (P＜0.05); 8h after the administration, medicine of the present invention large and small dosage group rat temperature and ordinary water group be more variant significance meaning (P＜0.05).
The result shows that the large and small dosage of GANMAOTONG granule can significantly suppress 10% young beer yeast pyrogenicity rat temperature and raise better antipyretic effect again.
2.4 medicine of the present invention is to the influence of immunization:
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, by body weight random packet (same 2.1.1 divides into groups), each organizes mouse stomach administration (the same 2.1.1 of dosage), and the ordinary water group is irritated stomach equivalent ordinary water, irritates stomach every day 1 time, and continuous 5 days, each was organized mice feed water inlet and is not limit.
30min after the last administration, every caudal vein injection india ink 0.1mL10g
-12min, 20min get blood 20 μ L with quantitative capillary tube by the mouse orbit rear vein beard respectively at the injection back, be dissolved in 0.1% the sodium carbonate liquor and shake up, put Agilent8453 spectrophotometer 650nm place and survey the absorbance A value, put to death mice, take by weighing liver, spleen weight respectively, calculate carbon clearance index K and proofread and correct carbon clearance index α.
K=(A
1-A
2)/(t
2-t
1), α=K
-3* body weight/(liver weight+spleen is heavy)
Table 8 medicine of the present invention is to the cytophagous influence of mouse monokaryon (x ± s)
| Group | Dosage/gkg -1 | Number of animals/only | K value/* 10 -2 | The α value |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 10 10 10 10 10 | 0.714±0.247 0.956±0.593 1.036±0.585 1.209±0.735 0.875±0.333 | 3.182±0.402 3.511±0.803 3.410±0.620 3.869±0.777 * 3.783±0.399 ** |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
The result shows, with the ordinary water group relatively, in the medicine of the present invention, small dose group is proofreaied and correct carbon clearance index α value that highly significant meaning (P＜0.05, P＜0.01) is all arranged.The result shows, in the medicine of the present invention, low dose of the cytophagous phagocytosis of mouse monokaryon is had significant facilitation.
2.4.2 medicine of the present invention is to the influence of mice serum hemolysin
[9]:
Get 50 of KM mices, male and female half and half, body weight (20 ± 2) g, be divided into 5 groups (groupings, the same 2.1.1 of dosage) at random, after the administration in the 1st day, each is organized mouse peritoneal and injects 5% normal saline chicken red blood cell suspension 0.2mL and carry out immunity, continue administration 5 days, every day 1 time.Each treated animal feed water inlet is not limit.
Behind the last administration 1h, pluck eyeball and get blood, centrifugal, get serum with 100 times of normal saline dilutions, get dilute serum 1mL, mix with 5% chicken erythrocyte suspension 0.5mL, 10% complement 0.5mL, after in 37 ℃ of calorstats, being incubated 30min, stopped reaction in 0 ℃ of ice, centrifugal, get supernatant in ultraviolet-visible spectrophotometer 540nm place colorimetric, survey absorbance.
The results are shown in Table 9.
Table 9 medicine of the present invention is to the influence of mice hemolysin level (x ± s)
| Group | Dosage/gkg -1 | Number of animals/only | Absorbance | Average raising rate |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 10 10 10 10 10 | 1.435±0.433 1.553±0.480 1.893±0.360 * 1.804±0.309 * 1.787±0.386 | - 8.2 31.9 25.7 24.5 |
Annotate: compare with the ordinary water group,
*P＜0.05.
Average raising rate=(administration group mean light absorbency-ordinary water group mean light absorbency)/ordinary water group mean light absorbency * 100%
The result shows that big or middle dosage group of medicine of the present invention and ordinary water group compare, and rat hemolysin level difference has highly significant meaning (P＜0.01).The result shows that medicine of the present invention is to the effect of increasing significantly of mice serum hemolysin level.
2.5 the bacteriostasis of medicine of the present invention
2.5.1 the external bacteriostasis of medicine of the present invention
[10]:
2.5.1.1 the mensuration of minimum inhibitory concentration (MIC):
Medicine preparation: be subjected to reagent thing medicine of the present invention to make the solution of 0.256g/mL (crude drug content), 103.4kpa autoclaving 20min, medicinal liquid with doubling dilution with nutrient broth and 10% calf serum nutrient broth (cultivating second streptococcus, streptococcus pneumoniae) dilution be 128,64,32,16,8,4,2,1,0.5, each 2mL of medicinal liquid of a 0.25mg/mL10 variable concentrations, other gets meat soup contrast, antibacterial contrast, medicinal liquid contrast, and more than operation is all carried out under aseptic condition.
Original bacteria liquid preparation: get each bacterial strain 1 Tremella aurantialba Bandoni et Zang respectively, be inoculated in the broth bouillon of 2mL (streptococcus, pneumococcal vaccination are in 10% calf serum nutrient broth) 37 ℃ of constant temperature culture 24h.
MIC measures: the original bacteria liquid of getting each bacterial strain is diluted to concentration with sterile saline and is about 10
7CFU/mL, getting each dilution of bacteria 0.1mL respectively adds in separately 10 drug liquid tubes and positive for bacteria control tube, after each manages 37 ℃ of constant temperature culture 24h, observe the upgrowth situation of antibacterial, cultivation back culture tube presents clear and bright, is asepsis growth, occur muddy, for bacteria growing is arranged, be minimal inhibitory concentration (MIC) with the lowest concentration of drug of asepsis growth, the results are shown in Table 10.
Table 10 medicine MIC of the present invention measurement result
| Bacterial strain | The strain number | FENGRE GANMAO KELI/mgmL -1MIC scope MIC50 MIC90 | Medicine/mgmL of the present invention -1MIC scope MIC50 MIC90 | |||||
| The second streptococcus | Clinical criteria | 10 1 | 16-64 16 | 32 | 64 | 8-32 8 | 16 | 32 |
| Gold Portugal bacterium | Clinical criteria | 10 1 | 16-128 16 | 32 | 64 | 16-64 16 | 32 | 64 |
| Streptococcus pneumoniae | Clinical criteria | 10 1 | 8-32 16 | 16 | 32 | 4-32 8 | 8 | 16 |
| Bacillus pyocyaneus | 5 | 8-64 | 16 | 32 | 8-32 | 16 | 32 | |
Above result shows, medicine of the present invention all has strong inhibitory action to beta hemolytic streptococcus, staphylococcus aureus, streptococcus pneumoniae, bacillus pyocyaneus are external.
2.5.1.2 the mensuration of minimum bactericidal concentration (MBC):
After measuring MIC, to not see that successively bacterial growth respectively manages culture and draw 0.1ml respectively and add on 2 agar nutrition plates (second streptococcus, streptococcus pneumoniae are cultivated with blood agar culture-medium), cultivate 18h for 37 ℃, average clump count is minimum bactericidal concentration (MBC) less than 5 minimum drug level on the counting plate, the results are shown in Table 11;
Table 11 XIAOER ZHIKE TANGJIANG MBC measurement result
| Bacterial strain | The strain number | FENGRE GANMAO KELI/mgmL -1MBC scope MBC50 MBC90 | Medicine/mgmL of the present invention -1MBC scope MBC50 MBC90 | |||||
| The second streptococcus | Clinical criteria | 10 1 | 16-64 16 | 32 | 64 | 16-32 8 | 16 | 32 |
| Gold Portugal bacterium | Clinical | 10 | 32-128 | 32 | 64 | 16-64 | 32 | 64 |
| Standard | 1 | 16 | 16 | |||||
| Streptococcus pneumoniae | Clinical criteria | 10 1 | 16-32 16 | 16 | 32 | 8-32 8 | 8 | 16 |
| Bacillus pyocyaneus | 5 | 16-64 | 16 | 32 | 16-32 | 16 | 32 | |
Above result shows, medicine of the present invention all has strong killing action to beta hemolytic streptococcus, staphylococcus aureus, streptococcus pneumoniae, bacillus pyocyaneus are external.
2.5.2 bacteriostasis in the medicine body of the present invention
[11]:
Experimental strain: 3 kinds of clinical isolates strains are selected in this experiment altogether for use, and beta hemolytic streptococcus, staphylococcus aureus and streptococcus pneumoniae are the clinical strains of Qingdao Municipal Hospital.
Prerun test: beta hemolytic streptococcus, staphylococcus aureus, streptococcus pneumoniae being got 1 Tremella aurantialba Bandoni et Zang respectively be inoculated in separately in the 2mL broth bouillon, after putting 37 ℃ of incubators and increasing bacterium 18h, is 10 with 10 times of doubling dilutions of 5% dry yeast suspension
-1, 10
-2, 10
-3, 10
-4, 10
-5Etc. different concentration, get the KM mice, body weight (20 ± 2) g, male and female have concurrently, 5 of every concentration groups, the bacterium liquid of every lumbar injection 0.5mL dilution is observed dead mouse situation in 4 days, and experimental therapy is chosen the bacterial concentration that makes mouse death rate 80-100% and is infected.
Experimental therapy: get the KM mice, male and female half and half, body weight 20 ± 2g, random packet, every strain antibacterial is established 5 groups, 20/group (the same 2.1.1 of grouping administration), the bacterial concentration selected with prerun dyes mouse peritoneal injection 0.5mL bacterium liquid inductance, in bacterial injection gastric infusion the previous day, the morning, afternoon each once, and behind the injection bacterium liquid 1h, 6h gastric infusion is once respectively, observe the dead number of elements of mice in 4 days then, calculate mortality rate, protective rate, X 2 test between group the results are shown in Table 12-14;
Table 12 medicine of the present invention is to the endogenous protective effect of beta hemolytic streptococcus infecting mouse
| Group | Dosage/gkg -1 | Number of animals/only | Death toll/only | Mortality rate/% | Protective rate/% |
| Ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 | 20 20 20 | 18 10 7 | 90 50 * 35 ** | - 44.4 61.1 |
| Middle dosage low dose | 9.9 4.9 | 20 20 | 9 11 | 45 ** 55 * | 50.0 38.9 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
Protective rate (%)=(ordinary water group mortality rate-administration group mortality rate)/ordinary water group mortality rate * 100%
The result shows, compares with the ordinary water group, and the big or middle dosage of medicine of the present invention, small dose group mortality difference have highly significant meaning (P＜0.01, P＜0.01, P＜0.05).Show that infecting in the mice body that medicine of the present invention causes beta hemolytic streptococcus has significant protective effect.
Table 13 medicine of the present invention is to the endogenous protective effect of infection of staphylococcus aureus mice
| Group | Dosage/gkg -1 | Number of animals/only | Death toll/only | Mortality rate/% | Protective rate/% |
| Dosage low dose in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 4.9 | 20 20 20 20 20 | 18 11 8 9 10 | 90 55 * 40 ** 45 ** 50 * | - 38.9 55.5 50.0 44.4 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
The result shows, compares with the ordinary water group, and the big or middle dosage of medicine of the present invention, small dose group mortality difference have highly significant meaning (P＜0.01, P＜0.01, P＜0.05).Show that medicine of the present invention has significant protective effect to infecting in the microbial mice body in golden Portugal.
Table 14 medicine of the present invention is to the endogenous protective effect of pneumococcal infection mice
| Group | Dosage/gkg -1 | Number of animals/only | Death toll/only | Mortality rate/% | Protective rate/% |
| Dosage in the ordinary water group FENGRE GANMAO KELI heavy dose | Equal-volume water 4.3 19.7 9.9 | 20 20 20 20 | 19 12 9 11 | 95 60 * 45 ** 55 ** | - 36.8 52.6 42.1 |
| Low dose of | 4.9 | 20 | 13 | 65 * | 31.5 |
Annotate: compare with the ordinary water group,
*P＜0.05,
*P＜0.01.
The result shows, compares with the ordinary water group, and the big or middle dosage of medicine of the present invention, small dose group mortality difference have highly significant meaning (P＜0.01, P＜0.01, P＜0.05).Show that infecting in the mice body that medicine of the present invention causes streptococcus pneumoniae has significant protective effect.
This product also has the effect of resisiting influenza virus preferably in addition.
The The acute toxicity tests of medicine of the present invention:
LD50 is surveyed to go out in medicine prerun test, thereby carries out the mice maximum dosage-feeding and measure, and recording mice, to irritate the stomach maximum dosage-feeding in one day be 549g/kg (crude drug/body weight), is equivalent to 477 times of people's clinical application amount, do not see that overt toxicity reacts.
The long term toxicity test result of medicine of the present invention:
During the administration, large, medium and small dosage group rat body weight and food ration change and matched group compares there was no significant difference, hematology, blood biochemical are learned every index testing result all in range of normal value, each organ macroscopy of large, medium and small dosage group and matched group relatively do not have significant difference, and finding and matched group more also do not have significant difference under each test period of coldrex heavy dose of group internal organs section mirror.Show that by test continuous 4 weeks of rat gavage the safe dose of coldrex more than 17.3g/kg.
The present invention treats the compound medicine of anemopyretic cold, has advantage evident in efficacy, that flavour of a drug are few, purity is high, side effect is little.The preparation method of medicine of the present invention has extraction ratio height, purity height, simple to operate, is fit to suitability for industrialized production.
The present invention is not limited to above-mentioned preferred forms, and other any identical with the present invention or akin products that anyone draws under enlightenment of the present invention all drop within protection scope of the present invention.
Claims (9)
1, a kind of compound medicine for the treatment of anemopyretic cold, the preparation parts by weight of raw materials proportioning that it is characterized in that the active component that it is contained is: 280～380 parts of Fructus Arctiis, 780～880 parts of Flos Loniceraes, 450～550 parts of Fructus Forsythiaes, 280～380 parts of Herba Menthaes, 280～380 parts of Herba Schizonepetaes, 450～550 parts of Radix Isatidiss, 280～380 parts of Rhizoma Et Radix Notopterygiis, 450～550 parts of Folium Isatidiss, Radix Glycyrrhizae 110-210 part.
2, the compound medicine of treatment anemopyretic cold as claimed in claim 1, the preparation parts by weight of raw materials proportioning that it is characterized in that the active component that it is contained is: 333 parts of Fructus Arctiis, 833 parts of Flos Loniceraes, 500 parts of Fructus Forsythiaes, 333 parts of Herba Menthaes, 333 parts of Herba Schizonepetaes, 500 parts of Radix Isatidiss, 333 parts of Rhizoma Et Radix Notopterygiis, 500 parts of Folium Isatidiss, 167 parts in Radix Glycyrrhizae.
3, as the compound medicine of claim 1,2 described treatment anemopyretic cold, the dosage form that it is characterized in that described compound medicine is a granule.
4, a kind of preparation method of compound medicine of treatment anemopyretic cold as claimed in claim 3 is characterized in that it may further comprise the steps: a: the extraction of Fructus Forsythiae, Flos Lonicerae, Herba Menthae, Herba Schizonepetae, Rhizoma Et Radix Notopterygii volatile oil; B: the inclusion of volatile oil; C: the extraction of Fructus Arctii, Radix Isatidis, Folium Isatidis, Radix Glycyrrhizae; D: the preparation of granule.
5, preparation method as claimed in claim 4, the extraction step that it is characterized in that described volatile oil is: Fructus Forsythiae, Flos Lonicerae, Herba Menthae, Herba Schizonepetae, Rhizoma Et Radix Notopterygii are added 4 times of water, soaked reflux, extract, volatile oil 4 hours 1 hour, get volatile oil, other collects by device respectively for aqueous solution after the distillation and medicinal residues.
6, preparation method as claimed in claim 5, the inclusion that it is characterized in that described volatile oil is: step a gained volatile oil is ground with 8 times of amount beta-schardinger dextrin-s, 16 times of water, the grinding gap is 5um, milling time is 20 minutes inclusions, 40 ℃ of drying under reduced pressure, pulverize, cross 40 mesh sieves, get the volatile oil inclusion complex.
7, preparation method as claimed in claim 6, it is characterized in that described Fructus Arctii, Radix Isatidis, Folium Isatidis, the extraction step of Radix Glycyrrhizae is: will extract medicinal residues and Fructus Arctii behind the volatile oil, Radix Isatidis, Folium Isatidis, Radix Glycyrrhizae mixes and adds 10 times in water respectively, 8 times, decoct 2 times, time was respectively 2 hours, 1 hour, collecting decoction, filter, aqueous solution when filtrate and extraction volatile oil after the distillation merges, being concentrated into relative density is the clear paste of 1.10～1.12 (60～75 ℃), put and be chilled to room temperature, slowly add ethanol while stirring, make and contain alcohol amount and reach 70%, left standstill 12 hours, the leaching supernatant reclaims ethanol and is concentrated into the clear paste that relative density is 1.20～1.22 (60～75 ℃).
8, preparation method as claimed in claim 7 is characterized in that the preparation process of described granule is: clear paste is mixed with volatile oil inclusion complex and dextrin, steviosin, make granule altogether.
9, preparation method as claimed in claim 8 is characterized in that it also comprises the packed step of granule, and described granule contains Arctiin for every bag and is no less than 50mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610111509A CN1903254B (en) | 2006-08-21 | 2006-08-21 | Compound medicine for treating wind-heat type cold and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610111509A CN1903254B (en) | 2006-08-21 | 2006-08-21 | Compound medicine for treating wind-heat type cold and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1903254A true CN1903254A (en) | 2007-01-31 |
| CN1903254B CN1903254B (en) | 2010-05-12 |
Family
ID=37672714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610111509A Expired - Fee Related CN1903254B (en) | 2006-08-21 | 2006-08-21 | Compound medicine for treating wind-heat type cold and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1903254B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526517A (en) * | 2011-12-21 | 2012-07-04 | 南方医科大学珠江医院 | Traditional Chinese medicinal composition for treating influenzas and preparation method thereof |
| CN104435796A (en) * | 2014-10-20 | 2015-03-25 | 安徽华泽医药有限公司 | Anti-cold traditional Chinese medicine preparation |
| CN107469034A (en) * | 2017-08-16 | 2017-12-15 | 河南中医药大学 | A kind of Chinese medicine for treating virus flu |
| CN109260309A (en) * | 2018-11-20 | 2019-01-25 | 山东罗欣乐康制药有限公司 | A kind of preparation method of the Chinese medicinal composition granules of warm in pain |
| CN114558102A (en) * | 2022-03-18 | 2022-05-31 | 湖北仙宠生物科技有限公司 | Chinese patent medicine formula for treating upper respiratory tract viral infectious diseases |
| CN116870051A (en) * | 2023-07-28 | 2023-10-13 | 修正药业集团长春高新制药有限公司 | Traditional Chinese medicine composition for treating wind-heat type common cold and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733148A (en) * | 2005-08-01 | 2006-02-15 | 刘安西 | Quick release percutaneous absorption Chinese traditional medicine paster for reducing ever and curing cold |
-
2006
- 2006-08-21 CN CN200610111509A patent/CN1903254B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526517A (en) * | 2011-12-21 | 2012-07-04 | 南方医科大学珠江医院 | Traditional Chinese medicinal composition for treating influenzas and preparation method thereof |
| CN102526517B (en) * | 2011-12-21 | 2014-06-04 | 南方医科大学珠江医院 | Traditional Chinese medicinal composition for treating influenzas and preparation method thereof |
| CN104435796A (en) * | 2014-10-20 | 2015-03-25 | 安徽华泽医药有限公司 | Anti-cold traditional Chinese medicine preparation |
| CN107469034A (en) * | 2017-08-16 | 2017-12-15 | 河南中医药大学 | A kind of Chinese medicine for treating virus flu |
| CN109260309A (en) * | 2018-11-20 | 2019-01-25 | 山东罗欣乐康制药有限公司 | A kind of preparation method of the Chinese medicinal composition granules of warm in pain |
| CN114558102A (en) * | 2022-03-18 | 2022-05-31 | 湖北仙宠生物科技有限公司 | Chinese patent medicine formula for treating upper respiratory tract viral infectious diseases |
| CN116870051A (en) * | 2023-07-28 | 2023-10-13 | 修正药业集团长春高新制药有限公司 | Traditional Chinese medicine composition for treating wind-heat type common cold and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1903254B (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101836691B (en) | Chinese medicinal herb feed additive | |
| CN104719671A (en) | Compound essential oil for preventing diarrhea of piglets as well as preparation method and application of compound essential oil | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| CN114073730A (en) | Traditional Chinese medicine composition for preventing or treating air-conditioning syndrome | |
| CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN100353953C (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN102861122B (en) | Preparation process of radix astragali and slender acanthopanax particles for veterinary use | |
| CN102526573A (en) | Medicament for treating child cold | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN105726792A (en) | Traditional Chinese medicine composition with effects of resisting periodontitis and protecting periodontium and preparation method and application thereof | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1405314A (en) | Cryptoporus volvatus fermented product, and its preparation method and application | |
| CN105726631A (en) | Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis | |
| CN1608662A (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1323668C (en) | Pharmaceutical compositions and its application | |
| CN1443073A (en) | Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof | |
| CN112807362B (en) | Traditional Chinese medicine composition for treating subacute thyroiditis in acute stage and preparation method and application thereof | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN101049345A (en) | A preparation for treating disease of oral cavity and gorge, and preparation method | |
| CN111084862B (en) | Traditional Chinese medicine oral liquid for preventing and treating lung heat cough and asthma of poultry and preparation method thereof | |
| CN101209329A (en) | Chinese medicinal oral liquid with heat-clearing and detoxication, lung-heat-clearing and cough-relieving efficacy | |
| CN1733194A (en) | Extract of combined Chinese traditional medicinal crops for curing diseases of respiratory system and extracting method | |
| CN101607032B (en) | Compound medicament for treating children cough and preparation method thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO HANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHU HONGLONG Effective date: 20100608 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266061 B20, NONGHAIYUAN, NO.316, HONG KONG EAST ROAD, QINGDAO CITY, SHANDONG PROVINCE TO: 266061 HANHE VILLAGE, SHAZIKOU SUB-DISTRICT OFFICE, LAOSHAN DISTRICT, QINGDAO CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100608 Address after: Laoshan District Shazikou Street office in Shandong Province, Qingdao City, 266061 Chinese Village Patentee after: Qingdao Hanhe Pharmaceutical Co., Ltd. Address before: 266061 Shandong Province, Qingdao city Hongkong Road No. 316 Nonghaiyuan B20 Patentee before: Zhu Honglong |
|
| C56 | Change in the name or address of the patentee |
Owner name: QINGDAO HUAHAI PHARMACEUTICAL RESEARCH INSTITUTE C Free format text: FORMER NAME: QINGDAO HANHE PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 266101 Shandong Province, Qingdao city Laoshan District Road No. 17 Keyuan four Building No. 3 Patentee after: QINGDAO HUAHAI PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. Address before: Laoshan District Shazikou Street office in Shandong Province, Qingdao City, 266061 Chinese Village Patentee before: Qingdao Hanhe Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20160821 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |